We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Phase Bioscience Announces Collaboration with Centocor Research and Development

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Phase Bioscience Announces Collaboration with Centocor Research and Development"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Phase Bioscience, Inc., (PhaseBio) has announced that Centocor Research and Development Inc. has licensed PhaseBio’s patented deltaPhase™ process for use in its research applications.

PhaseBio’s deltaPhase technology offers new solutions for the production and purification of protein-based therapeutics, including polypeptides, proteins or antibodies and provides substantial advantages over current biological production methods.

According to PhaseBio, the advantages seen with its process include: increased yields, high throughput and elimination of chromatography steps for final product purification. “We are extremely pleased that Centocor has decided to extend their successful collaboration with PhaseBio,” stated Clay B. Thorp, Chairman of the Board, Phase Bioscience, Inc.

Under the terms of the agreement, Centocor will have rights to utilize the deltaPhase technology in their research.